Mankind Pharma, BDR Pharma partner for COVID drug Baricitinib in India
Advertisement
New Delhi: Mankind Pharma has recently announced that the company has partnered with BDR Pharmaceuticals International Pvt. Ltd for distributing the Anti-COVID19 drug Baricitinib under the trademark BARIKIND that received restricted emergency use approval, for use in combination with remdesivir.
According to the partnership, BDR Pharma will be manufacturing and marketing the product under a royalty free, limited and non-exclusive voluntary license from Eli Lilly and Company and Mankind Pharma will be distributing the same.
Baricitinib received restricted emergency use approval, for use in combination with remdesivir, for treatment of suspected or laboratory confirmed coronavirus disease 2019 (COVID-19) in hospitalized adults, requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). Lilly received permission for restricted emergency use from Central Drugs Standard Control Organization, a division of Ministry of Health.
Speaking on the partnership Mankind Pharma, said, "It is our pleasure to be in this distribution partnership with BDR Pharma for the Anti-COVID19 drug Baricitinib. Together we aim to fight against COVID-19 and meet the medical needs to the society."
BDR Pharmaceuticals, added, "We are pleased to partner with Mankind Pharma for distribution and through this collaboration, we believe Baricitinib will reach every nook and corner of the country effectively which is the need of the hour. Baricitinib was studied to treat COVID 19 affected patients in various clinical trials based on which the Indian Regulator has given us the restricted emergency use approval to manufacture and market the drug in India."
Read also: Mankind Pharma launches Dapagliflozin brand Justoza for diabetes, heart failure, CKD
Mankind Pharma is the fourth largest pharmaceutical company in India headquartered in New Delhi, India.
Its products range from Pharma, OTC and FMCG brands like Manforce Condoms, Unwanted 72, Prega News, Gas-O-Fast, Health OK Tablets, Acnestar Gel, Betakind Gargle and many others.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.